

Fig. S2 Correlation of EV-associated BRN4 and BRN2 with clinicopathological parameters of mCRPC

Parameter*	Total n (%)	Relative EV-BRN4 expression		P-value	Total n (%)	Relative EV-BRN2 expression		P-value
		≤median exp	>median exp			≤median exp	>median exp	
<u>ENZ treatment</u>								
No	31/37 (84)	16/31 (52)	15/31 (48)	P=0.4186	35/41 (85)	20/35 (57)	15/35 (43)	P=0.0703
Yes	6/37 (16)	2/6 (33)	4/6 (67)		6/41 (15)	1/6 (17)	5/6 (83)	
<u>Gleason score of primary tumor</u>								
< or equal to 7	22/37 (59)	9/22 (41)	13/22 (59)	P=0.9653	23/41 (56)	12/23 (52)	11/23 (48)	P=0.5574
8	2/37 (5)	1/2 (50)	1/2 (50)		3/41 (7)	2/3 (67)	1/3 (33)	
9-10	10/37 (27)	4/10 (40)	6/10 (60)		11/41 (27)	4/11 (36)	7/11 (64)	
<u>Age at diagnosis</u>								
40-49	2/37 (5)	1/2 (50)	1/2 (50)	P=0.0910	2/41 (5)	-	2/2 (100)	P=0.3228
50-59	5/37 (14)	2/5 (40)	3/5 (60)		5/41 (12)	3/5 (60)	2/5 (40)	
60-69	17/37 (46)	9/17 (53)	8/17 (47)		20/41 (49)	12/20 (60)	8/20 (40)	
70-79	13/37 (35)	5/13 (38)	8/13 (62)		13/41 (32)	6/13 (46)	7/13 (54)	
80-89	-	-	-		1/41 (2)	1/1 (100)	-	
<u>Final Serum PSA</u>								
< or equal to median (433.6)	17/37 (46)	7/17 (41)	10/17 (59)	P=0.9429	19/41 (46)	9/19 (47)	10/19 (53)	P=0.6507
>median	20/37 (54)	8/20 (40)	12/20 (60)		22/41 (54)	12/22 (55)	10/22 (45)	

*Gleason score unknown for 3 cases